Method for analysis of oligonucleotide analogs

• US 7,264,925 B2
• Filed: 08/30/2001
• Issued: 09/04/2007
• Est. Priority Date: 08/30/2000
• Status: Expired due to Term

• Current Assignee: Sarepta Therapeutics, Inc.
• Original Assignee: Avi Biopharma, Inc.
• Inventors: Weller, Dwight D., Reddy, Todime Muralimohan
• Primary Examiner(s): Kim; Young J.
• Application Number:
  US09/943,458
• Publication Number:
  US 20020110819A1
• Time in Patent Office: 2,196 Days
• Field of Search: 435/6, 435/91.1, 435/70.1, 435/320.1, 435/91.2, 528/391, 528/403, 528/405, 528/406, 530/350, 536/23.4, 356/344, 436/161
• US Class Current: 435/6.16
• CPC Class Codes: C12Q 1/6816 characterised by the detection means C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6832 Enhancement of hybridisation reaction
• CPC Class Codes: C12Q 2525/107 incorporating a peptide nucleic acid
• CPC Class Codes: C12Q 2525/113 incorporating modified backbone
• CPC Class Codes: C12Q 2527/125 Specific component of sample, medium or buffer
• CPC Class Codes: C12Q 2563/107 fluorescence

Abstract

Disclosed are methods for separating, detecting, quantitating and/or isolating predominantly uncharged oligonucleotide analogs, by resolving duplexes of such molecules with complementary or near-complementary DNA or charged DNA analogs. The DNA or charged analog may be labeled for detection purposes.

Claims

1. A method of separating a population of duplexes, each comprising one of a population of different, substantially uncharged oligomeric analyte molecules and a specific probe molecule,

wherein said substantially uncharged analyte molecules are oligonucleotide analogs composed of linked subunits of which at least 90% are uncharged, and said specific probe molecule is a fully charged nucleic acid or fully charged nucleic acid analog,

the method comprising:

(a) applying to an ion exchange medium a mixture of (i) the different substantially uncharged analyte molecules and (ii) the specific probe molecule, under conditions such that the probe forms stable duplexes with a plurality of or all of the different substantially uncharged analyte molecules,

thereby forming a plurality of different probe-analyte duplexes, which differ from each other with respect to the presence, length or position of an unhybridized portion of the probe molecule, and

(b) separating said different probe-analyte duplexes from each other and from single stranded analyte or probe molecules within the medium.

2. The method of claim 1, wherein each analyte molecule has a nucleotide sequence selected from the group consisting of a selected sequence, different length fragments of the selected sequence, internal deletion or insertion variants of the selected sequence, mutation variants of the selected sequence, and combinations thereof.

3. The method of claim 2, wherein said deletion, insertion or mutation variants contain at most one such deletion, insertion or mutation per 8 nucleotides of the selected sequence.

4. The method of claim 2, wherein the probe includes a sequence complementary to the selected sequence.

5. The method of claim 4, wherein the probe has a length which is equal to, or up to 25% greater than, the length of the selected sequence.

6. The method of claim 2, wherein the probe includes a sequence complementary to an N−

1 internal deletion variant of the selected sequence, N being the length in nucleotides of the selected sequence.

7. The method of claim 6, wherein the probe has a length equal to said N−

1 deletion variant of the selected sequence.

8. The method of claim 7, wherein said conditions are such that said probe hybridizes to only said N−

1 deletion variant.

9. The method of claim 2, wherein variations in sequence or length among said analyte molecules occur within a given subregion of said selected sequence, and the probe is effective to stably hybridize to said subregion under the conditions of said applying and separating.

10. The method of claim 9, wherein the population contains analyte molecules which are N−

1 deletion variants of the selected sequence, and the probe has a sequence and length sufficient to stably hybridize to each analyte molecule, under the conditions of said separating, at a region of the analyte molecule containing a deletion site.

11. The method of claim 1, wherein all of said subunits are uncharged.

12. The method of claim 1, wherein the analyte molecules are selected from the group consisting of peptide nucleic acids, phosphotriester oligonucleotides, methylphosphonate oligonucleotides, morpholino oligomers, and chimeras of any member of this group with another member of this group or with DNA, 2′

-O-alkyl RNA, or 2′

-O-allyl RNA.

13. The method of claim 12, wherein the analyte molecules are morpholino oligomers.

14. The method of claim 13, wherein said morpholino oligomers have intersubunit linkages selected from the group consisting of phosphoramidate and phosphorodiamidate.

15. The method of claim 1, wherein the probe is selected from the group consisting of DNA, RNA, 2′

-O-alkyl RNA, 2′

-O-allyl RNA, phosphorothioate DNA, and chimeras thereof.

16. The method of claim 15, wherein the nucleic acid is DNA.

17. The method of claim 1, wherein the probe is labeled.

18. The method of claim 17, further comprising the step of detecting and quantitating a duplex of the labeled probe with at least one target analyte molecule in the population.

19. The method of claim 1, further comprising the step of isolating at least one said duplex.